| Vaccine candidate(developer/sponsor) | Technology | Phase of trial(participants) | Adverse effects | Immune response | Location | Duration |
| AZD1222(University of Oxford, AstraZeneca) | adenovirus vector | Phase II–III randomized, interventional (10,260) | pending Phase I report | pending Phase I report | United Kingdom | May 2020 to August 2021 |
| Ad5-nCoV(CanSino Biologics, Institute of Biotechnology of the Academy of Military Medical Sciences) | recombinant adenovirus type 5 vector | Phase II interventional trial for dosing and side effects (500) | Moderate over 7 days: 81% had fever, pain, fatigue | Neutralizing antibody and T cell responses | China | March 2020 to December 2020 |
| mRNA-1273(Moderna, US National Institute of Allergy and Infectious Diseases, BARDA) | lipid nanoparticle dispersion containing messenger RNA | Phase II dose-confirmation to evaluate safety, toxicity, and immunogenicity (600) | ^ fever, fatigue, headache, myalgia, and pain at the injection site | ^ dose-dependent neutralizing antibody response on two-dose schedule; undetermined durability | United States | May 2020 to August 2021 |
| BNT162 (a1, b1, b2, c2)(BioNTech, Fosun Pharma, Pfizer) | RNA | Phase I–II of four vaccines, randomized, placebo-controlled, dose-finding, vaccine candidate-selection (7600) | pending Phase I report | pending Phase I report | Germany United States | April 2020 to May 2021 |
| CoronaVac(Sinovac Biotech) | inactivated SARS-CoV-2 virus | Phase I–II randomized, double-blinded, single-center, placebo-controlled in Xuzhou (744); Phase I–II in Renqiu (422) | pending Phase I report | pending Phase I report | China | April 2020 to December 2020 in Xuzhou; May to July 2020 in Renqiu |
| INO-4800(Inovio Pharmaceuticals, CEPI, Korea National Institute of Health, International Vaccine Institute) | DNA plasmid delivered by electroporation | Phase I–II (40) | pending Phase I report | pending Phase I report | United States South Korea | April 2020 to November 2020 |
| unnamed(Chinese Academy of Medical Sciences) | inactivated SARS-CoV-2 virus | Phase I–II randomized, double-blinded, single-center, placebo-controlled in Sichuan (942) | China | June 2020 to September 2021 | ||
| AG0301-COVID19(AnGes Inc., AMED) | DNA plasmid | Phase I–II non-randomized, single-center, two doses (30) | Japan | June 2020 to July 2021 | ||
| COVID-19/aAPC(Shenzhen Geno-Immune Medical Institute) | lentiviral vector, pathogen-specific artificial antigen presenting dendritic cells | Phase I (100) | China | March 2020 to 2023 | ||
| LV-SMENP-DC(Shenzhen Geno-Immune Medical Institute) | lentiviral minigene vaccine, dendritic cells modified with lentiviral vector | Phase I (100) | China | March 2020 to 2023 | ||
| unnamed(Beijing Institute of Biological Products, Wuhan Institute of Biological Products) | inactivated COVID-19 virus (vero cells) | Phase I (288) | China | April 2020 to November 2021 | ||
| LNP-nCoVsaRNA(Medical Research Council Clinical Trials Unit at Imperial College) | messenger RNA | Phase I randomized trial (105), with dose escalation study (15) and expanded safety study (at least 200) | United Kingdom | June 2020 to July 2021 | ||
| NVX-CoV2373(Novavax) | SARS-CoV-2 recombinant spike protein nanoparticle with adjuvant | Phase I (131) | Australia | May 2020 to July 2021 | ||
| Gam-COVID-Vac Lyo(Gamaleya Research Institute) | non-replicating viral vector | Phase I (38) | Russia | June 2020 to August 2020 | ||
| GX-19(Genexine Consortium, International Vaccine Institute) | DNA | Phase I (40) | South Korea | June 2020 to June 2022 | ||
| SCB-2019(Clover Biopharm, GlaxoSmithKline) | spike protein trimeric subunit with GSK adjuvant | Phase I (150) | Australia | June 2020 to March 2021 | ||
| COVAX-19(Vaxine Pty Ltd) | recombinant protein | Phase I (40) | Australia | June 2020 to July 2021 | ||
| CVnCoV(CureVac, CEPI) | messenger RNA | Phase I (168) | Belgium, Germany | June 2020 to August 2021 | ||
| unnamed(Academy of Military Sciences, Walvax Biotech) | messenger RNA | Phase I (168) | China | June 2020 to December 2021 | ||
| unnamed(Anhui Zhifei Longcom Biologic Pharmacy Co. Ltd.) | recombinant protein subunit | Phase I (50) | China | June 2020 to September 2021 | ||
| unnamedMedicago (Governments of Canada and Quebec) | plant-derived virus-like particle, recombinant, using GSK adjuvant | Phase I, randomized, dose-ranging (180) | Canada | July 2020 to April 2021 |
